What it's for (Indications)
- Rocuronium bromide is a rapid-onset, intermediate-duration non-depolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
- Its rapid onset of action makes it particularly suitable for rapid sequence intubation (RSI) in emergency and critical care settings where immediate airway control is paramount.
- It is also utilized for facilitating mechanical ventilation in intensive care unit (ICU) patients, although continuous monitoring of neuromuscular function is essential in such prolonged applications to prevent over-paralysis and potential complications.
- The use of rocuronium should always be accompanied by adequate general anesthesia and analgesia, as it does not possess sedative or analgesic properties.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of rocuronium bromide must be individualized based on the patient's weight, age, renal and hepatic function, the anticipated duration of the procedure, the desired depth of neuromuscular blockade, and the concomitant use of other medications that may affect neuromuscular transmission. For rapid sequence intubation, an initial dose of 0.6 mg/kg to 1.2 mg/kg intravenous (IV) is typically administered. For routine intubation, a dose of 0.6 mg/kg IV is common. Maintenance doses generally range from 0.1 to 0.2 mg/kg IV, administered when twitch response returns to 25% of control. Alternatively, a continuous IV infusion can be initiated at 10-12 mcg/kg/min following recovery from the initial bolus dose, with subsequent adjustment based on neuromuscular monitoring. Lower doses are often recommended for patients with renal or hepatic impairment and the elderly due to altered pharmacokinetics. |
Safety & Warnings
Common Side Effects
- Rocuronium, while generally well-tolerated when used appropriately, can lead to several side effects.
- The most significant adverse reactions are related to its pharmacological action: prolonged neuromuscular blockade, which can result in residual paralysis post-operatively, manifesting as respiratory insufficiency or apnea.
- Cardiovascular effects, though less common than with some other neuromuscular blockers, can include transient increases in heart rate and blood pressure, or rarely, hypotension and bradycardia.
- Hypersensitivity reactions, including severe anaphylaxis, are a rare but life-threatening complication, characterized by bronchospasm, urticaria, flushing, and cardiovascular collapse.
- Other potential side effects include injection site reactions, rash, and edema.
- Careful patient monitoring and preparedness for managing these potential adverse events are crucial during its administration.
Serious Warnings
- Black Box Warning: Serious Warnings: Respiratory Arrest Risk and Need for Airway Management Rocuronium is a neuromuscular blocking agent that causes dose-dependent paralysis of skeletal muscles, including those essential for respiration. Its administration will result in respiratory arrest or clinically significant respiratory depression. Therefore, rocuronium must only be administered by or under the supervision of adequately trained clinicians experienced in the use of neuromuscular blocking agents and skilled in airway management and respiratory support. Facilities for endotracheal intubation, artificial respiration, oxygen administration, and monitoring of neuromuscular function must be immediately available and ready for use. The drug does not produce sedation or analgesia; therefore, it should always be administered in conjunction with adequate anesthesia and/or sedation. Patients may be fully awake and aware but unable to move or communicate if sedatives or anesthetics are insufficient. Prolonged duration of neuromuscular blockade beyond the desired clinical effect can occur, particularly in patients with renal or hepatic impairment, or in those with certain neuromuscular disorders, necessitating extended ventilatory support and vigilant monitoring.
- Rocuronium must be administered by or under the supervision of experienced clinicians familiar with its use and skilled in airway management, mechanical ventilation, and the management of respiratory arrest.
- Due to its paralytic effects, facilities for endotracheal intubation, artificial ventilation, and oxygen administration must be immediately available.
- Patients with myasthenia gravis or other neuromuscular diseases, severe electrolyte disturbances, or conditions potentiating neuromuscular blockade (e.
- g.
- , severe obesity, certain antibiotics like aminoglycosides) may have an exaggerated response to rocuronium.
- Hepatic and renal impairment can prolong its duration of action and recovery time, necessitating dose adjustments and careful monitoring.
- There is a risk of prolonged paralysis in critically ill patients, especially those receiving concomitant corticosteroids, requiring vigilant neuromuscular monitoring to avoid critical illness polyneuropathy or myopathy.
How it Works (Mechanism of Action)
Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that competitively antagonizes the action of acetylcholine at the nicotinic acetylcholine receptors located on the motor end-plate of skeletal muscles. By binding to these receptors without activating them, rocuronium prevents acetylcholine from initiating muscle contraction, thereby producing a flaccid paralysis. This competitive antagonism can be overcome by increasing the concentration of acetylcholine at the neuromuscular junction, which is typically achieved through the administration of acetylcholinesterase inhibitors such as neostigmine or pyridostigmine, or more recently, by specific encapsulating agents like sugammadex which directly binds to and inactivates rocuronium, providing a rapid reversal of blockade. The drug does not affect consciousness or pain perception.
Commercial Brands (Alternatives)
No other brands found for this formula.